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To the Editor,
Screening for antinuclear antibodies (ANA) by indirect 
immunofluorescence (IIF) is an important tool in the 
diagnosis of systemic rheumatic diseases [1, 2]. In recent 
years, digital systems for automated ANA-IIF analysis 
were introduced to overcome some of the major short-
comings of classical IIF (e.g. labor intensiveness, high 
inter-reader variability, risk for errors due to manual 
handling/ reporting and the considerable expertise 
needed). Recently, we and others evaluated the analyti-
cal performance of these platforms in comparison with 
conventional IIF [3–5]. Overall, the results were promising 
and it was suggested that automated IIF could improve 
harmonization and reduce the hands-on time and risk for 
human error [3]. Moreover, some of the observations (e.g. 
the quantitative measure as an alternative for end-point 
titration and an objective internal quality control [IQC] 
measure) might offer new opportunities for the routine 
laboratory [6]. Here, we describe 1 year of routine experi-
ence (from June 2013 to June 2014, 4699 samples analyzed) 
with an automated ANA-IIF system and evaluate whether 
our expectations were met.
In our center, HEp-2000 cells in combination with 
IgG conjugate are used (dilution 1:40) (Immunoconcepts, 
Sacramento, CA, USA). Slides are prepared using the PhD 
(Biorad, Hercules, CA, USA) or Zenit-Up (Menarini diag-
nostics, Florence, Italy) and analyzed automated on the 
Zenit G-sight (Menarini diagnostics, Florence, Italy). Zenit 
G-sight performs negative/positive interpretation based 
on the probability index (PI), the quantitative measure of 
the system. The PI cut-off values proposed by the manufac-
turer are PI < 8 (negative), PI > 50 (positive) and 8  ≤  PI  ≤  50 
(uncertain). In our laboratory, we use adapted cut-off 
values: PI < 8 (negative), PI > 26 (positive) and 8  ≤  PI  ≤  26 
(uncertain) (based on ROC analysis of both clinical as well 
as routine cohorts, for a description of the cohort used 
see Bonroy et al. 2013 [3]). Nevertheless, all samples are 
reviewed by expert technicians and the automated analy-
sis results are adapted whenever necessary. As all systems 
are linked to the laboratory information system (LIS), data 
transmission is automated.
First, we evaluated to what extend the software of the 
system can replace the expert for negative/positive correct 
classification, pattern recognition and intensity scoring. See 
Table 1 for an overview of the PI-based positive/negative cat-
egorization of the samples in comparison with the results 
obtained after visual review. Based on our in-house cut-off 
values, expert intervention for negative/positive correct 
classification was needed in 49% of the samples, with most 
interventions needed to reclassify ‘uncertains’ (43%). Expert 
interventions for true corrections of the system interpreta-
tion were limited (3.4% false negatives, 2.3% false positives 
[based on in-house cut-off values]). When manufacturer’s 
cut off values would have been applied, more interventions 
would have been needed (59%).
Zenit G-sight is programmed to recognize five mono-
specific patterns [3, 4]. We compared this function with 
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expert review of the digital images on a set of 500 con-
secutive positive routine samples analyzed between 
March and June 2014 (Supplemental Data, Table 1). Auto-
mated pattern assignment was higher in the monopattern 
samples (87%, 316/362) compared to multiple pattern 
samples (78%, 108/138). In 53% of the monopattern 
samples, automated pattern assignment needed correc-
tion (168/316). Globally, expert intervention was needed 
in 65% (276/424) of the automated assigned patterns.
Based on the correlation between expert intensity 
scoring (negative, 1+ to 5+) on the digital images and the 
PI provided by the Zenit G-sight (unpublished data), we 
apply an automated LIS-conversion of PI into intensity 
scoring to limit the number of clerical handlings. Using 
this automated conversion no expert adjustment was 
needed in 65% (n = 1844/2839) of the positive samples. 
Moreover, most adjustments (90%) were minor (difference 
of 1 intensity).
As suggested previously, automated ANA-IIF might 
reduce the hands-on time [3]. In this study, we evaluated 
this using a random routine run of 36 samples (3 slides, 
dilution 1:40). We observed that the hands-on time for 
reading of the digital images was more time consuming 
(7 min/36 samples) than the manual ANA-IIF microscopy. 
In contrast automated data transmission resulted in a 
gain of 25 min.
Next, we reviewed our IQC management approach. 
The IQC approach implemented in our center uses both 
IQC material (a negative and positive control [NC and 
PC]) as well as patient data (monitoring of the median PI 
values per run) and is based on Westgard multirules [6].
Between June 2013 and June 2014, 146 NC and PC 
measurements were performed. The PI results of the NC 
and PC samples are plotted in Figure 1. For the NC sample 
there were two isolated positive violations of the control 
rules, one +1S2 warning rule (April 1st) and one +1S3 (April 
8th) rejection rule. Further investigation of the raw images 
used for PI calculation revealed that in both an artifact 
falsely influenced the PI. For the PC, there were between 
June 2013 and mid-October 2013 several violations of 
the warning and rejection rules, some of them related to 
technical problems with our pipetting device as previ-
ously described in more detail [6]. Based on these observa-
tions, our pipetting device was put out of order resulting 
in a clearly better reproducibility of the PI measurements 
of the PC. Only one violation was observed after October 
2013, which was traced to an air bubble due to low control 
sample volume.
From June 2013 to June 2014, the daily median PI 
was 14 times outside the +2SD limit of the overall mean, 
three of them being major events. The first major event 
occurred in December 2013 and showed consecutive 
positive violations of the proposed control rules (four 
+1S3 and one +2S2 rejection rules). During this period no 
violations were observed for the PC or NC samples. Nev-
ertheless, an increase in the %ANA positives was seen in 
December 2013 (71%) compared to September 2013 (55%; 
χ² p < 0.0001) and October 2013 (64%; χ² p = 0.034). The 
increase was not due to a shift in the pathology grade, 
because the number of samples originating from the rheu-
matology department was even less during the violations 
(19%, 80/427) compared to stable periods (28%, 790/2851) 
[6]. We further investigated whether other variables (e.g. 
the introduction of new reagent lot or a new vial of conju-
gate with the same lot, the pipetting station) might have 
influenced the PI measurements. Indeed, this major event 
was linked to the switch of the pipetting device (from Zenit 
Up to PhD).
After January 2014, two isolated major violations (1S3) 
on the daily median PI occurred, respectively in March 
and May 2014, with a parallel increase of the %ANA posi-
tives (76% and 64%, respectively). During these viola-
tions, control measurements were normal. The violation 
in March could not be linked to a shift in pathology grade 
as the proportion of samples originating from the rheu-
matology department was only 21% (8/38). In contrast, 
in May we observed more rheumatology requests (36%). 
However, this proportion was not statistically higher than 
the pathology grade over several periods outside events 
(28%; χ² p > 0.05) [6].
To conclude, the implementation of automated 
ANA-IIF analysis in our routine laboratory resulted in 
Table 1: Overview of the PI-based positive/negative categorization of the samples in comparison with the results obtained after visual 
review.
Visual review of 
digital imagesa
   Negative PI < 8 (%)   Manufacturer’s cut-off values   In-house cut-off values
Uncertain 8  ≤  PI  ≤  50 (%)  Positive PI > 50 (%) Uncertain 8  ≤  PI  ≤  26 (%)  Positive PI > 26 (%)
Negative   811 (84%)  1012 (39%)  37 (3%)  939 (47%)  110 (6%)
Positive   159 (16%)  1568 (61%)  1112 (97%)  1078 (53%)  1602(94%)
a Percentages between brackets are proportions within the PI-based subsets.



































































Daily median patient PI
Figure 1: Levey-Jennings chart of the probability index (PI) of the negative control (NC), positive control (PC) samples, and daily median of 
patient PI.
Target value of PC1, PC2, PC3 and PC4 are respectively 87.6, 89.8, 89.6 and 89.4. The right y-axis indicates the Z-score of the PI against 
the target value. Single open circles indicate a 1S2 violation (warning rule); double open circles indicate a 22S or 13S violation (rejection rule). 
Horizontal lines indicate the target mean and standard deviation (SD) limits.
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important improvements in the context of expert burden 
and hands-on time. Expert intervention was necessary in 
49% of the samples for positive/negative interpretation 
and in 65% of the automatically assigned patterns.
Moreover, PI conversion into intensity scoring could 
be automated with only limited expert correction needed. 
We also showed an important reduction in hands-on-time 
compared to the classic ANA-IIF microscopy, mainly as 
a result of automated data transmission. The latter also 
implies a reduced risk for clerical errors. Finally, our 
results also illustrate the practical applicability of the pre-
viously proposed quantitative IQC approach. Using this 
approach in a routine setting, we observed only limited 
number of major violations and more important, all were 
shown to indicate relevant changes in the total process 
with need for further investigations to guarantee the 
quality of the results.
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